arrow
R

Ralph J. Hauke

Nebraska Cancer Specialists
H指数:36
被引数:5,809

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

57 Final Analysis of the TiNivo-2 Phase 3 Trial: Long-term Outcome of Tivozanib (Tivo) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

57 TiNivo-2 III期试验的最终分析:替沃扎尼(Tivo)在转移性肾细胞癌(mRCC)患者中的长期结局

2026-09-020
OAAI
Overview of tivozanib (tivo) safety in phase 3 clinical trials in patients with metastatic renal cell carcinoma (mRCC)

tivozanib (tivo) 在转移性肾细胞癌 (mRCC) 患者中 III 期临床试验的安全性概述

2025-10-010
OAAI
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer
2023-06-012
OAAI
PHASE II OF CD40 AGONISTIC ANTIBODY SOTIGALIMAB (APX005M) IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH METASTATIC MELANOMA WITH CONFIRMED DISEASE PROGRESSION ON ANTI-PD-1 THERAPY
2021-11-105
OA
CDX1140-01, A PHASE 1 DOSE-ESCALATION/EXPANSION STUDY OF CDX-1140 ALONE (PART 1) AND IN COMBINATION WITH CDX-301 (PART 2) OR PEMBROLIZUMAB (PART 3)
2020-11-098
PREAI
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
CANCER
IF5.1
2019-04-0520
OAAI
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes
2018-05-0199
PREAI
Androgen receptor (AR) mutations in patients (pts) with castration-resistant prostate cancer (CRPC) with and without prior abiraterone acetate (AA) treatment
2015-08-011
PRE